The list price for Camzyos (mavacamten) is $60,000 per year [1]. This translates to approximately $5,000 per month for the medication itself [1].
What insurance coverage is available for Camzyos?
Patients may be eligible for co-pay assistance programs if they have commercial insurance. For example, the MYCAMZYOS Program offers a co-pay card that could reduce out-of-pocket costs to as low as $10 per month for eligible patients [1]. However, this program does not apply to patients with government-funded insurance, such as Medicare, Medicaid, or TRICARE [1].
Are there patient assistance programs for Camzyos?
Beyond co-pay assistance for commercially insured patients, Bristol Myers Squibb, the manufacturer of Camzyos, offers the Bristol Myers Squibb Access Support Program. This program can provide free medication to eligible uninsured or underinsured patients who meet certain financial criteria [1]. To determine eligibility and enroll, patients or their healthcare providers can contact the program directly [1].
How is Camzyos administered and dosed?
Camzyos is an oral medication, taken by capsule [2]. Dosing is individualized and typically starts at 2 mg once daily. Dosage adjustments are made based on a patient's clinical response, including their left ventricular (LV) systolic function and the severity of their symptoms [2]. The maximum recommended dose is 25 mg once daily [2].
What are the approved uses for Camzyos?
Camzyos is approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to improve exercise capacity and functional status [2]. HCM is a condition where the heart muscle becomes abnormally thick [2].